AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Mirati Therapeutics Reports Second Quarter 2017 Financial Results August 3, 2017 <b>GBSI</b> Biopolicy Summit 2017 Explores Newest Lab Automation, Digital Tools And Technologies Promising Improved Preclinical Research Reproducibility — October 16 In San Francisco September 6, 2017 Boston Scientific To Participate In 2017 Healthcare Conference August 20, 2017
<b>GBSI</b> Biopolicy Summit 2017 Explores Newest Lab Automation, Digital Tools And Technologies Promising Improved Preclinical Research Reproducibility — October 16 In San Francisco September 6, 2017
